Location
Atreca, Inc.
835 Industrial Rd., Suite 400
San Carlos, CA 94070
United States
info@atreca.com
T +1.650.595.2595
F +1.650.453.2410
We are a biopharmaceutical company developing novel therapeutics based on a deep understanding of the human immune response.
We focus in a unique way on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies, including those in our lead programs in oncology.
The proprietary Atreca Discovery Platform has been validated repeatedly via partnerships with major pharmaceutical companies, non-profit foundations, academic institutions, and governmental entities. Our experienced leadership is supported by recognized technical advisors and leading investors dedicated to building a company with a worldwide and lasting impact on human health.
Mr. Orwin brings over 25 years of diverse experience in the biotechnology and pharmaceutical industries, having held senior positions at leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer, Genentech, and most recently Relypsa. During Mr. Orwin’s tenure at Relypsa, the company launched and commercialized its lead candidate, Patiromer (US brand name Veltassa®), and was acquired by Galenica (Vifor Pharma) in a transaction worth over $1.5 billion. Prior to Relypsa, he served as Chief Executive Officer and a member of the Board of Directors of Affymax. Previously, Mr. Orwin was Senior Vice President of the BioOncology Business Unit at Genentech (now a member of the Roche Group), where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech’s oncology portfolio in the United States. He has also held senior marketing and sales positions at Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhône-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation. Mr. Orwin received an M.B.A. from New York University and a B.A. from Rutgers University.
Dr. Bishop is an experienced executive and medical oncologist with extensive experience in cancer drug development. Prior to Atreca, Dr. Bishop was the CMO of Clover Biopharmaceuticals, a global biotech company focused on the development of vaccines and biologics. Previously, he was Executive Vice President and CMO at aratinga.bio, a developer of novel cancer immunotherapies. Before founding aratinga.bio in 2017, Dr. Bishop was Senior Vice President Hematology / Oncology at Gilead Sciences and held clinical development roles at Genentech, Johnson & Johnson and Sanofi-Aventis. Prior to his industry career, he held leadership positions at the U.S. Food and Drug Administration and National Institutes of Health.
Dr. Bishop received his M.D. from the University of Nevada School of Medicine followed by a residency in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute.
Dr. Dhawan brings more than 15 years of experience in project planning and execution in Biologics, Pharmaceuticals, Industrials and Agricultural products to Atreca. He is responsible for maintaining best in class project management competency as well as providing leadership and oversight to manage development of Atreca’s discovery, preclinical, and clinical-stage assets. Prior to joining Atreca, he was a program manager at DuPont. Prior to that, he was an associate director of R&D program management at Codexis, where he held several other positions of increasing seniority.
Dr. Dhawan received a BSc from the University of Rajasthan, India, a MSc in Chemistry from the Indian Institute of Technology, Kanpur, India, and a PhD in Chemistry from the University of Arizona. Dr. Dhawan is Project Management Professional (PMP) certified.
Dr. Gould was previously Executive Director, Translational Oncology at Genentech, where he led a team focused on developing tumor specific antibodies weaponized with immune-targeting arms or drug payloads for use in both hematologic and solid tumors. Prior to joining Genentech, Dr. Gould served as Senior Director, Oncology at Curis.
Dr. Gould received his Ph.D. from the University of Connecticut Health Center in Development Biology and held postdoctoral fellowships at the University of California San Francisco in the department of Orthopedic Surgery, and University of Virginia in the Department of Biology.
Ms. Phillips has deep experience leading corporate and transactional matters at public biopharmaceutical companies, including corporate governance, compliance, contracting, securities law matters and SEC reporting, financings, and employment law matters. Prior to Atreca, Ms. Phillips was the Vice President of Corporate Law at Global Blood Therapeutics where she led a broad range of legal activities prior to the company’s commercialization of its first product. Prior to Global Blood Therapeutics, she was Senior Counsel and then Vice President and Associate General Counsel at Relypsa where she led a wide variety of legal matters as the company transitioned from IPO through commercialization of its first product and acquisition by Galenica (Vifor Pharma). Prior to Relypsa, she was Corporate Counsel at Affymax. Earlier in her career, Ms. Phillips was a corporate attorney at the law firms of Morrison Foerster LLP and Reed Smith LLP where she represented biotechnology and technology companies in mergers and acquisitions, securities law matters and equity financings.
Ms. Phillips holds a J.D. from Georgetown University Law Center and a B.A. from the University of California, Berkeley.
Dr. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.
Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.
Mr. Atwood is former President and CEO as well as a founder of Cell Design Labs, a company focused on developing the human cell engineering technology from the UC San Francisco lab of Wendell Lim. Mr. Atwood is also a founder and Managing Director at Versant Ventures, a leading healthcare-focused venture capital firm, where he serves as a Managing Director. He has more than 15 years of operating experience in the biotechnology industry. Prior to launching his career in venture capital, Mr. Atwood was Founder, President, and Chief Executive Officer of Glycomed, a publicly traded biotechnology company.
Mr. Atwood also currently serves as a Board member at the public companies Clovis Oncology, Inc. (CLVS), OpGen, Inc. (OPGN), PhaseRx (PZRX), and Veracyte, Inc. (VCYT), where he is Chairman.
Mr. Atwood received a BS in Biological Sciences from the University of California, Irvine, an MS in Ecology from the University of California, Davis, and an MBA from Harvard Business School.
Ms. Ball is the CEO of Antiva Biosciences focused on developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by HPV. Before joining Antiva in 2023, she served as CEO of Soteria Biotherapeutics, Inc., from 2020-2022, as SVP of Corporate Strategy and CFO of Menlo Therapeutics, Inc., from 2017-2020 and as SVP and CFO of Relypsa, Inc., prior to the company’s acquisition by Galenica. Ms. Ball also served as SVP, Finance and Administration and CFO of KAI Pharmaceuticals, Inc. (acquired by Amgen) and Vice President, Finance at Exelixis, Inc. Before joining Exelixis, Ms. Ball was a senior manager in Ernst & Young’s life sciences audit practice. Ms. Ball holds a B.S. from Babson College. Ms. Ball also served on the Board of Directors of Forty Seven Inc. prior to the company’s acquisition by Gilead.
Mr. Berger is a biotechnology industry analyst with over twenty-five years of experience in capital markets and financial analysis. Mr. Berger was most recently a founder of the small-cap focused NEMO Fund at Sectoral Asset Management. He previously served as Managing Director, Equity Research, and Senior Biotechnology Analyst at J.P. Morgan Securities. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has been involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities, including the Genentech initial public offering.
Mr. Berger currently serves as a director of the public biotechnology companies Five Prime Therapeutics, Immune Design, Proteostasis, and ESSA Pharma, and he previously served as a director of public biotechnology companies Seattle Genetics, Aurinia Pharmaceuticals, and VaxGen. He is a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine. Mr. Berger received a BA in International Relations and an MA in International Economics from Johns Hopkins University, and an MBA from Harvard University.
Mr. Brady is the Chief Executive Officer of Tempest Therapeutics, a publicly listed biotechnology company, since June 2021. Previously, he served as the President and Chief Operating Officer at Tempest from September 2019 to June 2021. Prior to joining Tempest, he served in various leadership roles at Immune Design Corp., a publicly listed biopharmaceutical company, including as Executive Vice President, Strategy & Finance from May 2015 until their sale to Merck in 2019, and as Chief Business Officer from September 2013 to May 2015. Prior to Immune Design, Mr. Brady served in various leadership roles at 3-V Biosciences, Inc. (now known as Sagimet Biosciences Inc.), a biopharmaceutical company, including as Chief Business Officer from February 2011 to August 2013, and as Vice President, Corporate Development, Strategy and Operations from February 2010 to February 2011. From April 2007 to March 2010, Mr. Brady held various roles at Proteolix, Inc., a biopharmaceutical company, most recently serving as Vice President of Corporate Development. Mr. Brady received a B.A. in English from the University of Oregon, a J.D. from the University of the Pacific and an LL.M. from New York University School of Law.
Dr. Lacey, formerly Senior Vice President of Discovery Research at Amgen, possesses over 20 years of scientific and senior leadership experience within the life sciences, focused on creating new medicines to make a difference in the lives of patients worldwide. During his tenure at Amgen Dr. Lacey lead an organization of more than 1200 scientists across a portfolio of drug discovery and development projects in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience.
Prior to joining Amgen, he was on the faculty at Washington University in St. Louis, MO.
Dr. Lacey currently serves as a Board member for Nurix N.V. and Inbiomotion SL, and acts as an advisor to a number of academic institutions, biotechnology, and venture capital firms. Dr. Lacey received a bachelor’s degree in biology and an MD degree from the University of Colorado.
Dr. Ma is Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead, where she has served since June 2022. Prior to Gilead, Dr. Ma was Executive Vice President and Head of Technical Operations at Sana Biotechnology from 2019 to 2022, and from 1996 to 2019 she held various roles at Genentech/Roche related to analytical development, pharmaceutical development, quality, technical product management and supply chain. Dr. Ma received a B.S. in Chemical Engineering from University of Minnesota, and a Ph.D. in Chemical Engineering from Yale University.
Mr. Orwin brings over 25 years of diverse experience in the biotechnology and pharmaceutical industries, having held senior positions at leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer, Genentech, and most recently Relypsa. During Mr. Orwin’s tenure at Relypsa, the company launched and commercialized its lead candidate, Patiromer (US brand name Veltassa®), and was acquired by Galenica (Vifor Pharma) in a transaction worth over $1.5 billion. Prior to Relypsa, he served as Chief Executive Officer and a member of the Board of Directors of Affymax. Previously, Mr. Orwin was Senior Vice President of the BioOncology Business Unit at Genentech (now a member of the Roche Group), where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech’s oncology portfolio in the United States. He has also held senior marketing and sales positions at Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhône-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation. Mr. Orwin received an M.B.A. from New York University and a B.A. from Rutgers University.
Dr. Robinson is a founder of Atreca and is currently Associate Professor of Medicine in the Division of Immunology and Rheumatology of the Department of Medicine at Stanford University. At Stanford, he is Director of the Stanford Osteoarthritis Initiative and a co-lead of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network of the NIH. Dr. Robinson has been elected to the American Society of Clinical Investigation (ASCI) and the Henry Kunkel Society. He and his laboratory members invented the technology underlying Atreca’s Immune Repertoire Capture® technology.
Dr. Robinson is an inventor on twenty-one patent applications, and technologies developed in his Stanford and VA laboratories have been licensed to seven companies in the biotechnology industry.
Dr. Robinson was also a co-founder of Bayhill Therapeutics. Dr. Robinson received his BS, MD, and PhD degrees from Stanford University and completed his clinical training in internal medicine at the University of California, San Francisco.
Dr. Rolfe is Executive Vice President of Clinical and Pre-clinical Development and Pharmacovigilance and Chief Medical Officer at Clovis Oncology. At Clovis, Dr. Rolfe has overseen the development team that obtained approvals for Rubraca as an ovarian cancer treatment in the US and Europe and is responsible for all pre-and post-marketing medical activities. Dr. Rolfe has 20 years of drug development experience and has previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation, Cambridge Antibody Technology, UCB Inc. and Celltech Group plc.
Dr. Rolfe qualified in medicine at the University of Edinburgh. She undertook postgraduate medical training in London, UK and obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians (MRCP). She has specialist accreditation in Pharmaceutical Medicine from the UK General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine.
Dr. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.
Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.
Dr. Davis is Director of the Stanford Institute for Immunity, Transplantation, and Infection at Stanford University School of Medicine, where he is the Avery Family Professor of Immunology in the Department of Microbiology and Immunology. Dr. Davis is also an Investigator of the Howard Hughes Medical Institute. Dr. Davis is the author or co-author of more than 300 peer-reviewed articles and books, is a member of the National Academy of Sciences, and is the recipient of numerous awards and distinctions. Dr. Davis received his BA degree in molecular biology from Johns Hopkins University and his PhD degree in molecular biology from the California Institute of Technology. He was a postdoctoral fellow at the Laboratory of Immunology at the National Institutes of Health prior to joining Stanford.
Dr. Fong is Co-Leader, Cancer Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center, and Efim Guzik Distinguished Professor in Cancer Biology at the University of California, San Francisco. He has served on National Cancer Institute (NCI) Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)-Immunotherapy Task Force, and is a senior editor for Cancer Immunology Research. Dr. Fong is also the site principal investigator at UCSF for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN). Dr. Fong received his BA degree from Columbia University and his MD degree from Stanford University, also completing an oncology fellowship at Stanford before joining the medical staff there in 1999. He joined UCSF in 2002.
Dr. Kunkel has led successful clinical development programs at several life sciences companies, most recently as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals). Prior to this, she was Vice President of Clinical Development at Xencor, Inc., and began her career in industry as a clinical scientist at Genentech. Dr. Kunkel has advised multiple firms, including Chiron (acquired by Novartis), Genentech/Roche, Salmedics (acquired by Celgene), and Syndax, and currently is an advisor to Curis, Inc., and Stemcentrx, Inc. She also serves on the boards of directors of Amphivena Therapeutics, Tocagen, Inc., Harpoon Therapeutics, and Loxo Oncology. Prior to entering the biotechnology industry, Dr. Kunkel spent ten years in academic medicine, during which time she served as Director of the Lymphoma Division in the Division of Hematology/Oncology at University of California, Los Angeles. She obtained her bachelor’s degree in biology from University of California, San Diego, and her MD degree from the University of Southern California. She is board-certified in internal medicine and held board certifications in hematology and oncology.
Dr. Lanier is an American Cancer Society Professor and the J. Michael Bishop MD Distinguished Professor and Chairman of the Department of Microbiology and Immunology at the University of California San Francisco and is Leader of the Cancer Immunity Program of the UCSF Helen Diller Comprehensive Cancer Center and Director of the Parker Institute for Cancer Immunotherapy at UCSF. Dr. Lanier received his Ph.D. in Microbiology and Immunology from the University of North Carolina – Chapel Hill. After postdoctoral studies, first at the Lineberg Cancer Center at the UNC – Chapel Hill and then as a Damon Runyon – Walter Winchell Cancer Research Fellow at the University of New Mexico, he joined the Research & Development Department at the Becton Dickinson Monoclonal Center in Mountain View, California, advancing to Associate Director of Research and was a Becton Dickinson Research Fellow. In 1990, he joined the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California, where he advanced to Director of Immunobiology. In 1999, Dr. Lanier joined the faculty of UCSF. His research group studies Natural Killer (NK) cells, which recognize and eliminate cells that have become transformed or infected by viruses. In recognition of his scientific contributions he was awarded the William B. Coley Award for Distinguished Research in Basic Tumor Immunology from the Cancer Research Institute in 2002, in 2005 was given the Rose Payne Award for contributions to the field of Immunogenetics by the American Society for Histocompatibility and Immunogenetics, in 2010 was elected to the US National Academy of Sciences, and in 2011 was named a Fellow of the American Academy of Microbiology and elected to the American Academy of Arts and Sciences. He was awarded the 2001 Distinguished Service Award from the American Association of Immunologists and served as President from 2006-2007. Dr. Lanier serves on the Scientific Advisory Board of several pharma and biotech companies and research institutes.
Dr. Steinman is a founder of Atreca and is currently the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics in the Stanford University School of Medicine. From 2002 to 2011, Dr. Steinman chaired the Stanford University Program in Immunology. Research in his laboratory led to the development of the blockbuster drug Tysabri® (natalizumab), which is used to treat patients with multiple sclerosis and Crohn’s Disease. He has received numerous awards for his research and has been elected to both the National Academy of Sciences and the National Academy of Medicine.
Dr. Steinman served on the board of directors and headed the scientific advisory board at Centocor for ten years, until the company was acquired by Johnson & Johnson. Dr. Steinman also co-founded and served as a director of Neurocrine Biosciences and Bayhill Therapeutics, and he co-founded Nuon Therapeutics. Dr. Steinman received a BA from Dartmouth College and an MD from Harvard University.
We use cookies that are necessary to operate our website. At this time, it is required to accept cookies to access the Investor Relations and Career pages on our website. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference settings. For more information on the use of cookies or our use of data, see our Cookies Notice or our Privacy Notice >
